UPDATE: Piper Jaffray Initiates Galena Biopharma at Overweight on ImmunoRx Potential
Piper Jaffray initiated coverage on Galena Biopharma (NASDAQ: GALE) with an Overweight rating and a $2.50 price target.
Piper Jaffray commented, "Galena is a cancer immunotherapy company that is developing NeuVax, which could be a new blockbuster breast cancer adjuvant therapy. Galena should complete enrollment of the Phase III PRESENT trial this summer with 36-month Disease Free Survival (DFS) data in mid-2016. Galena is also developing a Folate Binding Protein E39 (FBP-E39) targeted vaccine in a Phase I/II ovarian and endometrial cancer trial with preliminary data at ASCO in June. We look for clinical progress and potential partnerships to drive shareholder value in 2013. Galena recently raised $24 million, which should fund the company into 2014."
Galena Biopharma closed at $1.55 on Friday.
Latest Ratings for GALE
|Mar 2016||Roth Capital||Maintains||Buy|
|Dec 2015||Cantor Fitzgerald||Upgrades||Sell||Hold|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.